4/A: Cellectar Biosciences Consultant Option Price Correction

Cellectar Biosciences files an amendment to a Form 4 to correct the exercise price of a stock option granted to consultant Loren Stefan.

Summary

• This filing is an amendment to a previously filed Form 4 by Loren Stefan, a consultant for Cellectar Biosciences, Inc.
• The amendment corrects the exercise price of a stock option previously reported.
• The stock option has a title of 'Stock option (right to buy)' and an exercise price of $2.69.
• The transaction date was July 8, 2026, with a deemed execution date of July 8, 2026.
• The option grants the right to acquire 15,000 shares of common stock.
• The option is set to vest in full on July 8, 2027, contingent upon the reporting person's continued service.
• The expiration date for the option is July 8, 2036.
• The reporting person beneficially owns 15,000 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily serving as a procedural correction of a prior disclosure without introducing new material financial information.

Positives

• Correction of a filing error demonstrates diligence in maintaining accurate public records.
• The stock option is exercisable, indicating potential future value for the consultant.
• The option vests in full on a specific date, providing a clear incentive for continued service.

Negatives

• The filing is an amendment, indicating an initial error in reporting the exercise price.

Risks

• The vesting of the option is subject to the reporting person's continued service, meaning failure to continue service would result in forfeiture of the option.
• The value of the stock option is dependent on the future performance and stock price of Cellectar Biosciences, Inc.

Future Outlook

The stock option is set to vest in full on July 8, 2027, subject to the reporting person's continued service. The option expires on July 8, 2036.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and option grants within the biotechnology sector, providing transparency on compensation and potential ownership changes.

Related Party Transactions

• The filing details a stock option granted to Loren Stefan, identified as a consultant, which represents a transaction between the company and a related party.

Stakeholder Impact

• Shareholders are informed of the corrected details regarding stock options granted to a consultant, ensuring transparency in compensation structures.
• Employees and consultants are provided with clear information on vesting schedules and terms of equity-based compensation.

Next Steps

• Loren Stefan must continue service through July 8, 2027, for the stock option to fully vest.
• The stock option can be exercised anytime between vesting and expiration, subject to its terms.

Key Dates

Keywords

Form 4, SEC Filing, Stock Option, Beneficial Ownership, Cellectar Biosciences, Consultant, Exercise Price, Vesting